8-K: XOMA Royalty Corp Acquires Pulmokine for $20 Million, Adding Phase 3 Asset Seralutinib to Portfolio

XOMA Royalty Corporation has acquired Pulmokine, Inc. for $20 million in cash, gaining an economic interest in the Phase 3 asset seralutinib, which is being developed for pulmonary arterial hypertension.

Summary

• XOMA Royalty Corporation acquired Pulmokine, Inc. for $20 million in cash.
• The acquisition includes an economic interest in seralutinib, a Phase 3 asset for pulmonary arterial hypertension (PAH).
• XOMA Royalty will also pay success-based consideration contingent on future development and commercial events to Pulmokine stockholders.
• The company's net royalties will range from the low to mid-single digits on commercial sales.
• XOMA Royalty retains up to $25 million in potential milestone payments related to seralutinib.
• Seralutinib is being developed and co-commercialized by Gossamer Bio, Inc., and Chiesi Farmaceutici S.p.A.
• This transaction marks XOMA Royalty's second whole-company acquisition in 2024.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the acquisition of a promising Phase 3 asset, but it also acknowledges the inherent risks and uncertainties associated with drug development. The sentiment is cautiously optimistic.

Positives

• The acquisition diversifies XOMA Royalty's portfolio with a late-stage asset.
• Seralutinib has the potential to address multiple cardio-respiratory conditions beyond PAH.
• The deal provides non-dilutive funding to Pulmokine's founders and stockholders.
• XOMA Royalty has the potential to earn significant milestone payments and royalties from seralutinib.
• The acquisition aligns with XOMA Royalty's strategy of acquiring future economics associated with pre-commercial therapeutic candidates.

Negatives

• The success of the acquisition is contingent on the future development and commercialization of seralutinib.
• The actual financial returns from seralutinib are uncertain and depend on clinical trial outcomes and market acceptance.
• The company is reliant on third-party licensees for the development and commercialization of the drug.

Risks

• The development of seralutinib may face setbacks or delays.
• The licensees may require substantial funds to continue development, which may not be available.
• There is no guarantee of a viable market for seralutinib.
• Regulatory approval for seralutinib is not guaranteed.
• The company's financial returns are subject to the success of its licensees.

Future Outlook

The company anticipates potential financial returns from seralutinib and its potential to address multiple cardio-respiratory conditions beyond PAH. However, these are forward-looking statements and are subject to risks and uncertainties.

Management Comments

• Brad Sitko, Chief Investment Officer of XOMA Royalty, stated that they acquired Pulmokine to add seralutinib to their growing royalty and milestone portfolio while creating a favorable outcome for Pulmokine's founders and stockholders.
• Management believes seralutinib has the potential to address several cardio-respiratory conditions beyond PAH in the future.
• Management stated that they continue to offer creative royalty capital solutions to access assets with the potential to deliver attractive returns to XOMA Royalty's diverse portfolio.

Industry Context

This acquisition reflects a trend in the biotechnology industry where royalty aggregators acquire rights to future revenue streams from promising drug candidates. It also highlights the increasing focus on treatments for pulmonary arterial hypertension.

Comparison to Industry Standards

• XOMA Royalty's acquisition of Pulmokine is similar to other royalty aggregator deals, such as those made by companies like DRI Healthcare and HealthCare Royalty Partners, which focus on acquiring royalty and milestone rights to late-stage drug candidates.
• The low to mid-single digit royalty rate is within the typical range for pharmaceutical royalty agreements, although the specific rate depends on the stage of development and market potential of the drug.
• The potential $25 million in milestone payments is a significant amount, but it is contingent on the successful development and commercialization of seralutinib, which is a common structure in biotech deals.
• Compared to other Phase 3 assets, seralutinib's potential in PAH is promising, but its success will depend on the clinical trial results and market competition.

Stakeholder Impact

• Shareholders may benefit from the potential financial returns of seralutinib.
• Employees of XOMA Royalty may be involved in the management of the new asset.
• Pulmokine's founders and stockholders have received non-dilutive funding.
• Patients with pulmonary arterial hypertension may benefit from the development of seralutinib.

Next Steps

• XOMA Royalty will continue to monitor the development of seralutinib.
• The company will work with its licensees to advance the drug through clinical trials and regulatory approvals.
• XOMA Royalty will continue to seek other opportunities to acquire royalty and milestone rights.

Key Dates

Keywords

XOMA Royalty, Pulmokine, Seralutinib, Acquisition, Royalty, Milestone Payments, Phase 3, Pulmonary Arterial Hypertension, Biotechnology, Gossamer Bio, Chiesi Farmaceutici